Abstract: An anti-canine CD16 polypeptide generally includes a CDR region of SEQ ID NO:5, a CDR region of SEQ ID NO:9, or a functional variant of either CDR region. An anti-canine CD64 polypeptide generally includes a CDR region of SEQ ID NO:13, a CDR region of SEQ ID NO:17, or a functional variant of either CDR region. The anti-canine CD16 polypeptide and anti-canine CD64 polypeptide may be incorporated into a therapeutic compound, a multispecific compound, a targeted imaging compound, or a capture assay device.

Abstract: This disclosure describes compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain. In an illustrative embodiment, the targeting domain selectively binds to an HIV antigen.

Abstract: An immunotherapy compound includes an NK cell engaging domain, an NK activating domain and a targeting domain. The targeting domain selectively binds to HER2, HERS, or the HER2/HER3 heterodimer complex and is operably linked to the NK activating domain and the NK cell engaging domain. The compound may be administered to a subject to induce NK-mediated killing of a cancer cell, to stimulate expansion of NK cells in the subject, and/or for treating cancer.

Abstract: Provided are compositions for activating NK cells to stimulate an immune response for treating cancer and other disorders. In one embodiment, the invention provides a compound comprising an NK engaging domain that binds to CD 16; an NK activating domain operably linked to the NK engaging domain; and a targeting domain that selectively binds to a target cell and is operably linked to the NK activating domain and the NK engaging domain, wherein the targeting domain binds to CLEC12A.

Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Abstract: In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging.

Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Abstract: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.

Abstract: In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging.

Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Abstract: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.

Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Abstract: The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders.

Abstract: The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders. Also featured are methods, compositions, and kits for selecting an appropriate treatment modality for a subject and/or treating a variety of disorders.

Abstract: Methods and composition involving genetically engineered targeting conjugates with reversed orientation of VL and VH chains are provided. For example, in certain aspects targeting conjugates comprising VL and VH chains of anti-CD22 and anti-CD19 are described. In a further aspect, the invention provides methods and targeting conjugates comprising therapeutic agents or diagnostic agents for delivery to B cells.

Abstract: The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), which are useful in, e.g., methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders such as, but not limited to, cancers and inflammatory disorders. Also featured are methods, compositions, and kits useful for selecting an appropriate treatment modality for a subject (e.g., a subject with a cancer or inflammatory disorder) and/or treating a variety of disorders such as cell proliferative disorders.

Abstract: The invention features vectors encoding immunotoxic fusion proteins containing targeting domains and toxic domains, targeting cells transduced with the vectors, methods of making the targeting cells, and methods of treating diseases (e.g., cancer) using both the vectors and the transduced cells.

Abstract: The invention provides fusion toxins that contain one or more regions of diphtheria toxin and a portion of urokinase-type plasminogen activator, as well as the nucleic acids that encode the fusion toxins and methods of using the fusion toxins.

Abstract: The invention provides fusion toxins that contain one or more regions of diphtheria toxin and a portion of urokinase-type plasminogen activator, as well as the nucleic acids that encode the fusion toxins and methods of using the fusion toxins.